What is William Blair’s Forecast for SPRY Q1 Earnings?

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Research analysts at William Blair lowered their Q1 2025 earnings per share (EPS) estimates for ARS Pharmaceuticals in a note issued to investors on Thursday, March 20th. William Blair analyst L. Hanbury-Brown now expects that the company will post earnings per share of ($0.35) for the quarter, down from their prior forecast of ($0.25). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.55) per share. William Blair also issued estimates for ARS Pharmaceuticals’ Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.39) EPS and FY2026 earnings at ($0.14) EPS.

A number of other research firms also recently issued reports on SPRY. Raymond James boosted their target price on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a “strong-buy” rating in a research report on Tuesday, January 14th. Oppenheimer began coverage on ARS Pharmaceuticals in a report on Monday, February 10th. They set an “outperform” rating and a $40.00 price objective for the company. Leerink Partners upped their price target on ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Finally, Scotiabank initiated coverage on ARS Pharmaceuticals in a research note on Friday, March 7th. They set a “sector outperform” rating and a $30.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $31.00.

ARS Pharmaceuticals Stock Performance

Shares of SPRY stock opened at $13.15 on Monday. ARS Pharmaceuticals has a fifty-two week low of $7.55 and a fifty-two week high of $18.51. The stock has a 50 day simple moving average of $12.13 and a two-hundred day simple moving average of $13.07. The company has a market cap of $1.28 billion, a P/E ratio of -25.78 and a beta of 1.03.

ARS Pharmaceuticals (NASDAQ:SPRY) last released its earnings results on Thursday, March 20th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.56. The firm had revenue of $86.58 million during the quarter, compared to analyst estimates of $15.46 million.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in SPRY. Wellington Management Group LLP increased its stake in ARS Pharmaceuticals by 0.6% in the 4th quarter. Wellington Management Group LLP now owns 163,252 shares of the company’s stock worth $1,722,000 after acquiring an additional 917 shares during the last quarter. Rhumbline Advisers raised its position in shares of ARS Pharmaceuticals by 2.9% during the 4th quarter. Rhumbline Advisers now owns 65,163 shares of the company’s stock valued at $687,000 after buying an additional 1,824 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of ARS Pharmaceuticals by 10.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 20,607 shares of the company’s stock worth $217,000 after acquiring an additional 1,962 shares during the last quarter. Mariner LLC lifted its holdings in shares of ARS Pharmaceuticals by 5.8% during the 4th quarter. Mariner LLC now owns 35,908 shares of the company’s stock worth $379,000 after acquiring an additional 1,972 shares during the last quarter. Finally, LPL Financial LLC grew its position in ARS Pharmaceuticals by 11.4% in the fourth quarter. LPL Financial LLC now owns 21,408 shares of the company’s stock worth $226,000 after acquiring an additional 2,190 shares in the last quarter. Institutional investors own 68.16% of the company’s stock.

Insider Transactions at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, Director Laura Shawver sold 49,600 shares of the business’s stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $11.21, for a total transaction of $556,016.00. Following the sale, the director now owns 210,346 shares of the company’s stock, valued at $2,357,978.66. The trade was a 19.08 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Eric Karas sold 10,000 shares of the company’s stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $14.00, for a total value of $140,000.00. Following the sale, the insider now owns 7,696 shares in the company, valued at approximately $107,744. This represents a 56.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 159,600 shares of company stock worth $1,866,516 in the last ninety days. Company insiders own 40.10% of the company’s stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.